Eisai Co., Ltd. is a research-driven global pharmaceutical company headquartered in Tokyo, Japan. Founded in 1941 by Toyoji Naito, Eisai focuses on the discovery, development, manufacture and commercialization of prescription medicines and related healthcare products. The company emphasizes neuroscience and oncology as core therapeutic areas and invests in both small-molecule and biologic research to address unmet medical needs.
Among its well-known products, Eisai developed and markets Aricept (donepezil), a widely used treatment for the symptoms of Alzheimer’s disease, and LENVIMA (lenvatinib), an oncology therapy for several tumor types. In collaboration with Biogen, Eisai co-developed lecanemab (brand name Leqembi), an anti-amyloid antibody for early Alzheimer’s disease that gained regulatory approval in the United States in 2023. Beyond marketed medicines, Eisai maintains a pipeline of investigational drugs and combination therapies aimed at disease-modifying approaches for neurodegenerative conditions and targeted cancer treatments.
Eisai operates internationally, with manufacturing, research and commercial facilities across Japan, North America, Europe and other regions of Asia. The company pursues strategic collaborations and licensing arrangements with biotechnology and pharmaceutical partners to expand clinical development capabilities and global reach. Its activities span clinical development, regulatory affairs, pharmacovigilance, and commercialization to bring therapies from laboratory research to patients worldwide.
Guided by a corporate philosophy often described as “human health care,” Eisai positions itself as a company focused on improving patient outcomes and quality of life. Its long history in pharmaceuticals and continued emphasis on R&D and partnerships underpin its efforts to develop new treatments in neurology and oncology while expanding access to existing therapies across multiple geographies.
AI Generated. May Contain Errors.
